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Effect of maternal calcium supplementation on offspring blood
pressure in 5- to 10-y-old rural Gambian children1–3
Sophie Hawkesworth, Yankuba Sawo, Anthony JC Fulford, Gail R Goldberg, Landing MA Jarjou, Ann Prentice,
and Sophie E Moore
ABSTRACT
Background: Evidence suggests that increased maternal calcium
intake during pregnancy may result in lower offspring blood pres-
sure, prompting calls for more robust data in this field, particularly
in settings of habitually low calcium intake.
Objective: The objective was to investigate the effect of maternal
calcium supplementation on blood pressure in offspring by recruiting
children born after a randomized, double-blind, placebo-controlled
trial of calcium supplementation during pregnancy.
Design: Children (n = 389) from a rural area of The Gambia (mean
age: 7.4 6 1.2 y; range: 5–10 y), whose mothers received a calcium
supplement (1500 mg Ca/d from 20 wk of gestation until delivery) or
placebo, were followed up in West Africa. Blood pressure was as-
sessed under standardized conditions with use of the Omron 705IT
automated oscillometric device (Morton Medical Ltd, London, United
Kingdom), and anthropometric and body composition (bioelectrical
impedance) measurements were also made.
Results: The analysis was restricted to 350 children born at term,
which represented 64% of original trial births. There was no differ-
ence in systolic (adjusted mean difference: 20.04 mm Hg; 95% CI:
21.78, 1.69 mm Hg) or diastolic (adjusted mean difference: 0.25 mm
Hg; 95% CI: 21.27, 1.77 mm Hg) blood pressure between children
whose mothers had received calcium and those who received placebo.
No interaction between childhood body mass index (in kg/m2; mean:
14.0) and maternal calcium supplementation was observed in this
study.
Conclusion: Calcium supplementation in the second half of preg-
nancy in Gambian women with very low habitual calcium intakes
may not result in lower offspring blood pressure at 5–10 y of
age. Am J Clin Nutr 2010;92:741–7.
INTRODUCTION
A large number of studies have reported an inverse association
between birth weight and blood pressure in later life. These have
been extensively reviewed (1, 2) and are interpreted as revealing
the importance of fetal nutrition for the ‘programming’ of blood
pressure. Calcium is considered to be a key factor in the regu-
lation of blood pressure throughout life (3) and particularly
during pregnancy, when calcium supplementation in high risk
women and/or thosewith low calcium intakes may reduce the risk
of pregnancy-induced hypertension (4). Mechanisms linking
calcium intake in pregnancy to offspring blood pressure are not
yet determined but may involve the setting of calcium regulating
hormones such as parathyroid hypertensive factor (5).
There is some evidence from observational studies that in-
creased calcium intake during pregnancy, either from food (6) or
from supplements (7), may be related to lower blood pressure in
the offspring, although this association has not been universally
observed (8). To date only 3 randomized controlled trials of
maternal calcium supplementation during pregnancy have pub-
lished follow-up data on blood pressure among the offspring (9–
11). One of these showed an overall effect of maternal calcium
supplementation on reduced offspring blood pressure at 2 y of age
in the United States (9). Although there was no effect on mean
offspring blood pressure, an Argentinean trial of maternal cal-
cium supplementation reported a decreased risk of having high
blood pressure [defined by age, sex, and height-specific cutoffs
(12)] in the offspring at 7 y (10). In addition, there was an
interaction with child body mass index (BMI); the maternal
intervention was associated with lower blood pressure in offspring
with higher BMI (kg/m2) (10). Most recently, an Australian trial
showed no association between maternal calcium supplementa-
tion and offspring blood pressure at 4–7 y of age (11).
Calcium intake during pregnancy in rural areas of The Gambia
is much lower than international recommendations, typically
300–400 mg/d (13–15), and close to the estimated biological
requirement. We have conducted a large randomized, placebo-
controlled trial of calcium supplementation of pregnant women
from 20 wk of gestation until delivery. The primary outcome of this
trial was the effect on systolic blood pressure at 36 wk of gestation.
Here we present the results of a follow-up study conducted on the
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offspring when they were 5–10 y old. The primary objective of this
study was to investigate the effect of maternal calcium supple-
mentation on offspring blood pressure; secondarily, we investigated
a possible interaction with offspring BMI (10).
SUBJECTS AND METHODS
Between November 2005 and August 2006 in The Gambia,
West Africa, we undertook a follow-up study of children whose
mothers had participated in a randomized, placebo-controlled
trial of calcium supplementation during pregnancy. The study
was part of a European Union consortium investigation of the
early life nutritional determinants of disease (Framework 6:
‘Early Nutrition Programming Project’). The original supple-
mentation trial is registered on the International Standard Ran-
domized Controlled Trial Number Register as ISRCTN96502494
and is described briefly below. To date, outcomes in a subset of
the mothers and infants studied in detail have been reported (16).
Maternal calcium supplementation trial
Between 1995 and 2000, all pregnant women from 16 villages
in the rural West Kiang region of The Gambia were invited to
participate in a double-blind, randomized, placebo-controlled
trial of calcium supplementation (1500 mg Ca/d provided as 3750
mg calcium carbonate or cellulose-lactose placebo) from 20 wk
of pregnancy (P20) until delivery. Study participants were ran-
domized, with use of published tables, in blocks of 4 to ensure an
even distribution of participants from different seasons. Maternal
antenatal care was stratified by 3 clinic blocks corresponding to
areas overseen by the 3 trial midwives (16). The primary outcome
of the study was maternal blood pressure at 36 wk of gestation
(measured in 536 women), and 546 live singleton infants were
deemed to be delivered at term.
Follow-up study
Scientific approval for the cross-sectional follow-up study
was granted by the Medical Research Council (MRC) The
Gambia Scientific Coordinating Committee and ethical per-
mission was granted by the joint Gambian Government and
MRC The Gambia Ethics Committee and the London School of
Hygiene and Tropical Medicine Ethics Committee. Community
sensitization meetings were held in relevant villages, and
support was gathered from village elders and school head
teachers. Fully informed consent was obtained from the parents
or guardians of participating children. All field staff and
investigators (except the code holder, AP) remained blinded to
the treatment group of the subjects.
At the time of this follow-up study, the surviving offspring
were aged between 5 and 10 y (mean age: 7.4 y, SD 6 1.2).
Recruitment was limited to those children still residing in West
Kiang or within an hour’s drive from the MRC laboratories at
the urban/peri-urban coastal areas (n = 452).
Study measurements
Measurements were conducted by fully trained fieldworkers
following standard operating procedures. An automated oscil-
lometric monitor (Omron 705IT; Morton Medical Ltd, London,
United Kingdom) was used to measure blood pressure following
guidelines from the American Heart Association (17). Subjects
were seen in the early morning (0800–1000) before breakfast,
they were seated at rest for 5 min before the first measurement,
and readings were continued until 3 were within 5 mmHg of each
other. Additional readings were taken on a separate day for any
children with unusually high blood pressure readings, as defined
by the United States National Heart, Lung and Blood Institute
guidelines (18). These subjects were referred to a physician if
readings remained high; if the second series of readings was
within the normal range, these values were entered in the database
to be used in the analysis. The average of the 3 blood pressure
readings was used to estimate systolic and diastolic blood
pressure. Pulse pressure was calculated as systolic – diastolic
pressure, and mean arterial pressure was calculated as diastolic +
(1/3 · pulse pressure).
Anthropometric measurements included height, weight,
midupper arm circumference, and triceps skinfold thickness.
These were assessed using standard techniques by the same fully-
trained fieldworker (98% of measurements) to minimize observer
bias. Equipment was calibrated daily, weight was measured to the
nearest 0.1 kg with use of digital scales (Tanita; Chasmors Ltd,
London, United Kingdom), height was measured with use of
a stadiometer (Seca 214; Chasmors Ltd) to the nearest 0.1 cm,
and BMI was defined as weight(kg)/height(m)2.
We used the Tanita BC-418MA (Chasmors Ltd) segmental
bioelectrical impedance analyzer to assess body composition.
Impedance measurements were converted into an estimate of
percentage fat-free mass (FFM) from prediction equations that
were previously generated in this population with use of deu-
terium oxide dilution as the reference method. Details of this
validation study (19) and of the equation used (20) have been
published elsewhere. Percentage fat mass (FM) was calculated by
difference (% FM = 1002% FFM). Log-log regression analysis,
described by Wells et al (21), was used to assess the relation of
FM and FFM with height (Ht) and to generate FM and FFM in-
dices that were uncorrelated with height by using the value of the
slope variable from the regression equation. FM index (FMI) was
calculated as FM/Ht1.6 and lean mass index (LMI) was calculated
as FFM/Ht2.3. We used the Tanita analyzer’s inbuilt equations for
an estimate of percentage trunk fat (indicating central adiposity),
because it had not been possible to create population-specific
prediction equations for segmental body regions.
Statistical analysis
All statistical analysis was conducted with use of Stata 10
(Stata Corporation, College Station, TX), and all outcome
variables and continuous covariates were normally distributed.
An intention-to-treat analysis with use of linear regression was
used to assess the relation between supplementation status of the
mother (calcium compared with placebo) and blood pressure in
the offspring. Variables that were potential correlates of blood
pressure were assessed by simple linear regression and those
that were associated were included in the adjusted regression
models. The analysis was first conducted as a simple main
effects model, then any interaction of the intervention effect
with age, sex, maternal baseline (P20, before start of supple-
mentation) BMI, maternal baseline blood pressure (measured
with Dinamap Pro 400, Critikon Ltd, United Kingdom), and
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child body composition was assessed by fitting interaction terms
in a sequential manner.
We investigated the impact of the intervention on the odds of
having high blood pressure by using logistic regression adjusted
for the same covariates. Children were defined as having high
blood pressure if their systolic blood pressure was above the 95th
percentile with use of age and height specific reference data (18).
We also ran an “as-treated” analysis relating the number of
tablets a woman consumed to her offspring’s blood pressure. Two
observational (nonrandomized) variables determined the number
of tablets consumed: the duration of time that the woman was in
the trial and her compliance, defined as a percentage (observed
tablets consumed/expected tablets to consume) with treatment.
The models were fitted with these 2 variables in addition to the
calcium dose consumed, which was defined as the interaction
among compliance, time in the study, and treatment group
(calcium compared with placebo).
RESULTS
A total of 389 children (193 born to calcium-supplemented
mothers and 196 born to mothers who received placebo) were
enrolled into the follow-up study, representing 86% of those
eligible and 71% of the original trial births (Figure 1). The main
reason for nonrecruitment (7.6% of calcium supplement children
and 7.0% of placebo children) was due to family movement
within The Gambia, resulting in eligible subjects being un-
available during the follow-up study period.
Recruitment
There were minor differences in available characteristics be-
tween those recruited and those not recruited into the present
follow-up (Table 1). The mothers of recruited individuals were
on average 1.8 y older and had slightly lower baseline (P20)
systolic blood pressure (21.7 mm Hg) than the mothers of in-
dividuals not enrolled into the follow-up study. Children in the
follow-up study were on average slightly shorter (20.1 cm) in
length at 2 wk of age compared with those lost to follow-up.
Thirty-eight of the enrolled children were classified as having
a gestational age,37 wk, as assessed by their Dubowitz score at
delivery (22), and were excluded from the analysis. One blood
pressure measurement was missing, because the child refused to
cooperate, leaving a final sample of 350 (171 born to calcium-
supplemented mothers and 179 to placebo mothers) for analysis,
representing 64% of original trial births.
Intention-to-treat analysis
Mean systolic blood pressure was 97.6 (SD6 8.1) mm Hg for
boys and 98.6 (SD 6 8.8) mm Hg for girls (Table 2). Mean
diastolic blood pressure was 57.2 (SD 6 7.3) mm Hg for boys
and 58.7 (SD 6 7.5) mm Hg for girls. The reliability of the
blood pressure measurement was 97% for the systolic and 86%
for the diastolic measurement. There was no difference in blood
pressure between children born to women who received calcium
or placebo during pregnancy (Table 3). The fully adjusted mean
difference in systolic blood pressure between the groups was
0.29 mm Hg (95% CI: 21.41, 1.98; P = 0.74) and for diastolic
blood pressure was 0.38 mm Hg (95% CI: 21.13, 1.90; P =
0.62). Only 4% of children had a systolic blood pressure that
was above the 95th percentile for their height and age; the odds
of having high blood pressure was not related to the maternal
calcium intervention (unadjusted odds ratio: 1.1; 95% CI: 0.4,
3.1; P = 0.86).
Interactions with maternal calcium supplementation
The possibility of the intervention effect being modified by
covariates was assessed by fitting interaction terms into the linear
regression models. There was a significant interaction between
maternal baseline blood pressure and the effect of the in-
tervention on childhood systolic blood pressure (interaction
coefficient, b = 0.26 mm Hg/mm Hg; 95% CI: 0.06, 0.46; P =
0.01). For women with low baseline systolic blood pressure, the
calcium intervention was associated with lower child systolic
blood pressure compared with placebo, whereas for women with
high blood pressure this association was reversed.
No other maternal variables (BMI or antenatal clinic attended)
were found to modify the effect of the intervention (data not
shown). Neither age nor sex of the offspring were shown to be
effect modifiers (data not shown), but there was a significant
interaction between the maternal intervention and child height
at follow-up on offspring systolic blood pressure (interaction
coefficient, b = 20.23 mm Hg/cm; 95% CI: 20.44, 20.02; P =
0.03). For shorter children, the maternal calcium intervention
was associated with higher blood pressure compared with
placebo, whereas for taller children it was associated with lower
blood pressure. There was no interaction between the mater-
nal intervention and any of the remaining anthropometric
FIGURE 1. Flow of subjects from the original calcium supplementation
trial who were recruited into the present follow-up.
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measurements (weight, BMI) or body composition (FMI, LMI,
trunk fat) variables on child blood pressure (data not shown).
As-treated analysis
The mean number of calcium tablets consumed by women in
the intervention arm was 422 (range: 267–561) and in the placebo
arm it was 415 (range: 285–588). For both intervention and
control women, mean compliance was 98% (range: 75–100%),
and there was no difference in mean compliance between the
calcium and placebo arms of the trial (calcium: 98%, placebo:
98%, t test P = 0.43). The as-treated analysis (Table 4) suggests
that women who demonstrated greater compliance had offspring
with higher systolic blood pressure (regression coefficient: 0.30 mm
Hg/%, 95% CI: 0.01, 0.59, P = 0.04). However, there was no
association between the amount of calcium consumed (modeled
by the dose consumed term) and offspring blood pressure,
suggesting that the compliance term was reflecting an associa-
tion with an unmeasured characteristic that correlated with
compliance. Offspring diastolic blood pressure was also not
associated with the maternal calcium dose (Table 4).
DISCUSSION
This study found no evidence that maternal calcium supple-
mentation (1500 mg Ca/d) of rural Gambian women during the
TABLE 2
Characteristics of children enrolled into the follow-up study whose mothers participated in a trial of calcium
supplementation during pregnancy1
Placebo Supplement
Males (n = 88) Females (n = 83) Males (n = 87) Females (n = 93)
Age (y) 7.4 6 1.2 7.3 6 1.2 7.5 6 1.2 7.3 6 1.2
Systolic BP (mm Hg) 97.0 6 8.1 99.3 6 9.0 98.1 6 8.1 97.9 6 8.7 [92]
Diastolic BP (mm Hg) 57.1 6 7.2 58.7 6 7.1 57.3 6 7.5 58.6 6 7.8 [92]
Pulse pressure (mm Hg)2 39.9 6 6.4 40.6 6 6.1 40.9 6 6.8 39.3 6 5.8 [92]
MAP (mm Hg)3 70.4 6 6.9 72.2 6 7.3 70.9 6 7.0 71.7 6 7.6 [92]
Height (cm) 118.3 6 7.8 118.8 6 8.7 118.4 6 7.4 117.3 6 7.9
HAZ4 21.13 6 0.77 20.81 6 1.02 21.18 6 0.84 21.12 6 0.75
Weight (kg) 19.6 6 2.8 20.0 6 4.1 20.1 6 3.4 19.1 6 3.2
BMI (kg/m2) 14.0 6 0.9 14.0 6 1.2 14.3 6 1.1 13.8 6 1.2
FMI (kg/m1.6) 1.88 6 0.38 [85] 2.51 6 0.62 [81] 2.01 6 0.49 [86] 2.39 6 0.55 [92]
LMI (kg/m2.3)3 11.59 6 0.77 [85] 11.12 6 0.73 [81] 11.76 6 0.80 [86] 11.02 6 0.82 [92]
Trunk fat (%)5 13.4 6 2.5 [85] 14.4 6 3.0 [81] 13.8 6 2.9 [86] 14.1 6 2.7 [92]
1 Values are means6 SDs; placebo and supplement refer to maternal intervention. Numbers in brackets reflect subject
numbers that differ from those indicated in the column headings. MAP, mean arterial pressure; HAZ, height-for-age z score;
FMI, fat mass index; LMI, lean mass index; BP, blood pressure.
2 Calculated as systolic – diastolic blood pressure.
3 MAP calculated as diastolic + (1/3 · pulse pressure).
4 Estimated from UK 1990 reference data (26).
5 Estimated by the Tanita inbuilt equations, not from population-specific equations.
TABLE 1
Differences between recruited individuals and those lost to follow-up1
Recruited
Placebo
(n = 196)
Supplement
(n = 193)
Lost to follow-up
(n = 157) P value2
Maternal age (y) 27.6 6 7.2 [127] 28.3 6 6.7 [122] 26.1 6 6.7 [93] 0.03
Maternal baseline weight (kg)3 55.0 6 6.9 [195] 54.9 6 6.7 [192] 55.3 6 8.1 [156] 0.4
Maternal height (cm) 1.60 6 5.5 159.9 6 5.2 159.7 6 5.6 0.6
Maternal baseline systolic BP (mm Hg)3 101.9 6 9.1 101.0 6 8.2 103.2 6 10.0 0.04
Maternal baseline diastolic BP (mm Hg)3 55.8 6 7.8 54.7 6 7.3 56.5 6 6.9 0.09
Child weight at 2 wk (kg)4 3.35 6 0.49 [194] 3.33 6 0.50 [191] 3.35 6 0.56 [136] 0.1
Child length at 2 wk (cm)4 50.9 6 2.0 [194] 50.5 6 2.0 [191] 50.8 6 2.4 [136] 0.08
1 Values are means6 SDs; placebo and supplement refer to maternal intervention; lost to follow-up defined as all live,
singleton children born during original trial who were not recruited into follow-up study (ie, includes those ineligible for
current follow-up). Numbers in brackets reflect subject numbers that differ from those indicated in the column headings. BP,
blood pressure.
2 P values are derived from independent t tests to assess the difference in mean values between those recruited (as
a total) and those lost to follow-up.
3 Baseline for original supplementation trial was 20 wk of gestation (P20) before commencement of supplementation.
4 Anthropometric measurements at 2 wk of age were used as a proxy measure for birth weight due to a large number of
missing data at the earlier age point.
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second half of pregnancy was associated with offspring blood
pressure at 5–10 y of age. This is consistent with a recent study
from Australia (11) and is one of the first reports from a region of
habitually very low dietary calcium intake.
A recent systematic review of the literature relating maternal
calcium intake (from both observational studies and randomized
controlled trials) to offspring blood pressure found that meth-
odological flaws and small study sizes prohibited strong con-
clusions (23). In the present study we were able to recruit 86% of
eligible children with only minor differences, in the available
characteristics, between those recruited and those lost to follow-
up. In contrast, the only trial to report an overall association
between maternal calcium supplementation and offspring blood
pressure suffered losses to follow-up of over 90% (9). In ad-
dition to the intention-to-treat analysis, our as-treated analysis
provided no evidence that the amount of calcium consumed by
the study women was associated with offspring blood pressure,
despite an association with compliance irrespective of treatment
arm.
A comparable trial in Argentina reported that the intervention
was associated with a reduced risk of the offspring having high
blood pressure at 5–9 y (10), an effect that has not been replicated
in our study. The Argentinean follow-up also reported an in-
teraction between the intervention and childhood BMI; for
individuals with a BMI above the mean (15.7), maternal calcium
supplementation was associated with lower systolic blood
pressure (10). In contrast to these findings, in the current study we
did not find that the effect of the maternal intervention was
modified by childhood BMI or by FMIs and LMIs of body
composition. This inconsistency in findings may be explained by
differences in the range of BMI; only 7% of subjects in our study
would be classified as having a BMI in the top 2 quartiles of the
Argentinean study. In the current study we observed an in-
teraction with child height, with the intervention tending toward
lower blood pressure in taller individuals, and we also observed
that maternal baseline blood pressure modified the interaction
effect. We are cautious of overinterpretation of these interaction
analyses, however, which could reflect chance findings due to
multiple testing.
There are a number of limitations to the current study that
should be raised. First, although we were able to recruit 86% of
eligible children, the analysis involved only 66% of children
born to mothers receiving calcium and 62% of those born to
mothers receiving the placebo. Loss to follow-up is a well-
recognized issue for long-term follow-up studies within this
research field, and these rates of loss are relatively low for
a study with a 5–10 y follow-up time scale (24). Recom-
mendations have highlighted the importance of providing clear
study details, which we have done by providing information on
subject recruitment rates and characteristics associated with
loss to follow-up (24). In this study loss to follow-up was as-
sociated with maternal baseline blood pressure; recruited
children had been born to women with slightly lower blood
pressure. This represents a potential selection bias but one we
were able to adjust for in our analysis of the effect of the
maternal intervention.
A related issue is the reduced sample size as a consequence of
subject attrition, which affects study power. In this study the
TABLE 4
Maternal calcium intake and offspring blood pressure: as-treated analysis1
Systolic blood pressure
(n = 350) P value
Diastolic blood pressure
(n = 350) P value
mm Hg mm Hg
Maternal compliance2 0.30 (0.01, 0.59) 0.04 1.89 (20.06, 0.44) 0.14
Duration of supplementation 0.52 (21.00, 2.05) 0.50 1.07 (20.26, 2.41) 0.12
Maternal calcium dose3 20.00 (20.004, 0.004) 0.83 0.00 (20.004, 0.004) 0.94
1 Results are the effect (95% CI) on child’s blood pressure of a 1-unit increase in exposure variable (compliance,
duration, or dose), derived from unadjusted linear regression analysis.
2 Compliance calculated as a percentage: (observed tablet consumption/expected tablet consumption).
3 Calcium dose fitted as an interaction term among compliance, time in study, and treatment allocation (supplement vs
placebo).
TABLE 3
Effect of maternal calcium supplementation on offspring blood pressure: intention-to-treat analysis1
Model 1 (n = 350) Model 2 (n = 348) Model 3 (n = 341) Model 4 (n = 341)
(95% CI) P value (95% CI) P value (95% CI) P value (95% CI) P value
Systolic pressure (mm Hg) 20.10 (21.89, 1.68) 0.91 20.04 (21.78, 1.69) 0.96 0.37 (21.32, 2.06) 0.67 0.29 (21.41, 1.98) 0.74
Diastolic pressure (mm Hg) 0.10 (21.46, 1.67) 0.90 0.25 (21.27, 1.77) 0.75 0.48 (21.03, 2.00) 0.53 0.38 (21.13, 1.90) 0.62
Pulse pressure (mm Hg) 20.20 (21.53, 1.12) 0.76 20.29 (21.60, 1.01) 0.66 20.12 (21.42, 1.18) 0.86 20.11 (21.41, 1.20) 0.87
Mean arterial pressure
(mm Hg)
0.03 (21.49, 1.55) 0.97 0.14 (21.33, 1.62) 0.85 0.44 (21.01, 1.89) 0.55 0.34 (21.11, 1.80) 0.64
1 Results are the difference in mean blood pressure (95% CI) for individuals born to women receiving calcium supplements compared with placebo
during pregnancy derived from linear regression analysis. Model 1: unadjusted. Model 2: adjusted for age, sex, antenatal clinic, maternal baseline [P20 (20 wk
of gestation)] BMI, and maternal baseline blood pressure. Model 3: adjusted as in model 2 but additionally adjusted for child height, lean mass index, and fat
mass index. Model 4: adjusted as in model 3 but additionally adjusted for maternal compliance (observed tablet consumption/expected tablet consumption)
and length of supplementation.
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precision estimate for the effect of maternal calcium supple-
mentation on offspring systolic blood pressure ranged from
21.41 to 1.98 and effects within this range therefore cannot
be discounted. However, it is arguable whether effect sizes of
this magnitude would be meaningful from a public health
standpoint.
The overall lack of an association between maternal calcium
supplementation and offspring blood pressure in this study may
reflect that additional calcium was not transferred to the off-
spring in utero (14, 15). In an analysis of a subset of mothers
and their infants, we found that maternal calcium supple-
mentation had no effect on fetal growth, bone mineral accretion
of infants in their first year, or breast milk calcium concen-
tration (16). This suggests that even when habitual calcium
intake is extremely low, physiologic adaptations may operate
that override any effects of supplementation and provide both
the mother and developing fetus with their calcium require-
ments (16). Alternatively, it may be that in this setting of
general undernutrition any potential benefits of calcium sup-
plementation are not seen.
Another explanation for the lack of association may relate to
the age of the children. Studies that have reported lower offspring
blood pressure in relation to maternal calcium intake during
pregnancy (either trial or observational data) have mainly in-
cluded children aged 2 y and under (6, 7, 9), whereas 3 studies
reporting no association were in children aged 3 (25), 4–7 (11),
and 7–10 y (8). McGarvey et al (6) reported an inverse association
between maternal self-reported calcium intake (from food and
personal supplements) and offspring systolic blood pressure at
1 mo of age, which was no longer apparent by 12 mo, although
recruitment was greatly reduced at the second follow-up. Sim-
ilarly, maternal calcium supplement use in Project Viva was
associated with reduced offspring blood pressure at 6 mo (7), but
there was no longer an association at 3 y (25). It may be that any
influence of maternal calcium intake is short-lived and/or does
not track into later childhood. In addition, the background cal-
cium intakes of the 3 published intervention studies are very
different from the intakes of Gambian women involved in this
study; in the United States, Hatton et al (9) reported the average
baseline calcium intake of women enrolled in their trial was over
1000 mg/d compared with 300–400 mg/d in The Gambia (16).
These discrepancies may help to explain the differential effects of
the maternal intervention in these settings.
In conclusion, we found no evidence that maternal calcium
supplementation of 1500 mg/d from 20 wk of gestation until
delivery influences offspring blood pressure measured at 5–10 y
of age in a rural area of The Gambia.
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